An open-label, parallel study of evolocumab in subjects with or without hepatic impairment

Trial Profile

An open-label, parallel study of evolocumab in subjects with or without hepatic impairment

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Evolocumab (Primary)
  • Indications Hypercholesterolaemia; Hyperlipoproteinaemias
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 09 Nov 2016 New trial record
    • 26 Sep 2016 Results published in the Journal of Clinical Pharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top